Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 29, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Market Cap	37	74	31	-	-	-
Market Cap Growth	26.45%	137.21%	-	-	-	-
Enterprise Value	20.29	57.21	9.14	0	0	0
Last Close Price	2.30	4.63	2.28	-	-	-
PB Ratio	0.57	1.16	0.47	-	-	-
P/TBV Ratio	2.60	5.23	1.59	-	-	-
Debt / Equity Ratio	-	0	0	0	0.01	0.00
Net Debt / Equity Ratio	-0.27	-0.27	-0.33	-0.37	-0.40	-0.40
Net Debt / EBITDA Ratio	1.53	1.53	1.33	1.79	0.53	2.78
Net Debt / FCF Ratio	1.91	1.91	1.49	1.86	1.72	2.52
Quick Ratio	7.92	7.92	11.53	14.09	8.41	13.56
Current Ratio	8.10	8.10	11.77	14.26	8.59	13.89
Return on Equity (ROE)	-14.74%	-14.55%	-19.89%	-19.82%	-48.15%	-11.98%
Return on Assets (ROA)	-16.39%	-15.98%	-22.96%	-14.76%	-40.99%	-15.31%
Return on Invested Capital (ROIC)	-22.48%	-22.48%	-33.84%	-22.68%	-63.86%	-34.95%
Return on Capital Employed (ROCE)	-16.82%	-16.46%	-23.54%	-17.45%	-51.88%	-16.74%
Buyback Yield / Dilution	-36.59%	-36.59%	-26.85%	-28.16%	-21.09%	-148.46%
Total Shareholder Return	-36.59%	-36.59%	-26.85%	-28.16%	-21.09%	-148.46%

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Jun 18, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 29, 2026

Data Sources Report a data error